NAD+ and Metabolic Syndrome: What Three Human Trials Actually Found

Written by the Nuvirox Research Team

Short answer: no, at least not based on the human trials completed so far. Metabolic syndrome — the cluster of high blood sugar, elevated blood pressure, excess abdominal fat, and abnormal cholesterol that raises cardiovascular risk — is exactly the kind of condition mouse studies suggested NAD+ precursors should help with. But when researchers tested nicotinamide riboside in actual overweight, insulin-resistant humans across multiple trials, the core metabolic benefits mice showed did not show up.

Why did researchers expect NAD+ precursors to help with metabolic syndrome?

In mice fed a high-fat diet, nicotinamide riboside consistently improved insulin sensitivity, protected against weight gain, and enhanced oxidative metabolism through NAD+-dependent sirtuin activation. Given that metabolic syndrome in humans involves very similar biology — insulin resistance, mitochondrial dysfunction, low-grade inflammation — it was a reasonable and well-motivated hypothesis to test NR as a potential intervention in humans with these same problems.

What happened when this moved to human trials?

The honest answer is that most short-term human trials in overweight or obese adults have failed to show the metabolic improvements the mouse data predicted. Researchers who have reviewed this literature directly acknowledge that "most short-term clinical trials conducted so far have not reported positive outcomes" for adiposity and insulin sensitivity, even while NAD+ levels themselves reliably rise with supplementation. That gap between raising NAD+ and improving metabolic outcomes is one of the more important honest findings in this entire field.

What human studies actually show

Dollerup et al., 2018 (RCT, n not obese men, 12 weeks, NR 2,000 mg/day). Published in the American Journal of Clinical Nutrition, this placebo-controlled trial in obese, insulin-resistant men found 12 weeks of NR appeared safe but did not improve insulin sensitivity or whole-body glucose metabolism compared to placebo.

Remie et al., 2020 (crossover RCT, n=13, 6 weeks, NR 1,000 mg/day). This randomized, double-blind, placebo-controlled crossover study in healthy overweight or obese men and women used detailed metabolic phenotyping, including a hyperinsulinemic-euglycemic clamp (a gold-standard insulin sensitivity test). The conclusion: NR supplementation did not affect muscle mitochondrial function or insulin sensitivity, though it did alter body composition and skeletal muscle acetylcarnitine concentrations.

The twin study (n=28, 5 months, escalating to 1,000 mg/day). The longest human trial in this space found NR improved systemic NAD+ metabolism, muscle mitochondrial biogenesis, and gut microbiota composition — but explicitly did not ameliorate adiposity or overall metabolic health, even with a much longer treatment duration than the other trials — the same study discussed in our NAD+ and gut microbiome review.

What NAD+ supplementation won’t do for metabolic syndrome

Based on the completed human trials, an NAD+ precursor supplement should not be expected to meaningfully improve insulin sensitivity, blood glucose, or body fat on its own. The evidence-based approaches for metabolic syndrome remain dietary changes, physical activity, weight management, and, where indicated, prescribed medications for blood pressure, cholesterol, or blood sugar — all with far stronger human outcome data.

If you have been told you have metabolic syndrome, prediabetes, or insulin resistance, that's worth managing directly with your doctor using approaches with proven track records, rather than substituting a supplement for lifestyle changes or prescribed treatment.

Dosing and what a realistic timeline looks like

Across these trials, doses ranged from 1,000 mg to 2,000 mg per day of NR for 6 to 12 weeks, with the longer 5-month twin study using an escalating dose up to 1,000 mg/day. None of these windows produced the core metabolic benefits mouse studies predicted, which suggests this isn't simply a matter of needing more time at these doses — the human metabolic response appears to genuinely differ from the mouse response.

Frequently asked questions

Can NAD+ supplements help with insulin resistance?

Multiple placebo-controlled human trials in overweight, insulin-resistant adults have not found an improvement in insulin sensitivity from nicotinamide riboside, despite promising mouse data.

Why did mouse studies show a benefit that didn’t show up in humans?

This happens often in metabolic research. Mice on high-fat diets may respond differently to NAD+ precursors than humans with chronic, longstanding metabolic syndrome, and dosing relative to body weight differs substantially between species.

Does NAD+ supplementation do anything measurable in people with metabolic syndrome?

Yes — it reliably raises blood NAD+ levels and, in longer trials, has affected muscle mitochondrial biogenesis and gut microbiota. It just hasn’t moved the core metabolic syndrome markers like insulin sensitivity or adiposity.

What should someone with metabolic syndrome actually focus on?

Diet, physical activity, weight management, and any medications prescribed by your doctor for blood pressure, cholesterol, or blood sugar have far stronger evidence for improving these outcomes than any NAD+ supplement currently has.

Does NAD+ supplementation lower blood pressure in metabolic syndrome?

One earlier trial in healthy middle-aged and older adults suggested a potential effect on blood pressure and arterial stiffness worth further study, but the dedicated metabolic syndrome trials discussed above, focused specifically on insulin sensitivity and adiposity, did not find broader metabolic improvements.

Is there any population where NAD+ precursors have shown clearer metabolic benefits?

The longer, 5-month twin study did find improvements in muscle mitochondrial biogenesis and gut microbiota composition, suggesting duration may matter for some outcomes, even though adiposity and overall metabolic health didn't improve in that same study.

The bottom line

This is one of the clearer cases in NAD+ research where mouse promise did not survive contact with human trials. Nicotinamide riboside reliably raises NAD+ levels, but three separate human studies in overweight, insulin-resistant adults found no meaningful improvement in insulin sensitivity or metabolic health. Anyone managing metabolic syndrome should lean on approaches with stronger human evidence.

References

1. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353. PMID:29992272.
2. Remie CME, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426. PMID:32320006.
3. Pirinen E, et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci Adv. 2023. doi:10.1126/sciadv.add5163.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.